<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="= âˆ’7.8â€‰kcal/mol) for 3CLpro and Dolutegravir (Î&quot;G = âˆ’9.4â€‰kcal/mol) and" exact="Bictegravir" post="(Î&quot;G = âˆ’8.4â€‰kcal/mol) for 2â€²-OMTase]. After the extensive computational"/>
 <result pre="After the extensive computational analysis, we proposed that Raltegravir, Paritaprevir," exact="Bictegravir" post="and Dolutegravir are excellent lead candidates for these crucial"/>
 <result pre="four genera: alpha, beta, delta and gamma, out of which" exact="alpha" post="and beta coronaviruses (CoVs) are known to infect humans"/>
 <result pre="protein-drug complexes at the long-interval. Table 3. Interaction details of" exact="Paritaprevir" post="and Raltegravir with 3CLpro. S/No DrugBank ID HB D"/>
 <result pre="DrugBank ID HB D (Ã…) Pi-SR D (Ã…) vdWISR 1." exact="Paritaprevir" post="(DB09297) Ser46 2.33 Met49 Leu50 Cys145 Pro168 5.27 3.85,"/>
 <result pre="ID EBE (kcal/mol) EIC (M) Molecular formula Chemical scheme 1" exact="Paritaprevir" post="(DB09297) âˆ’9.8 65.52â€‰nM C40H43N7O7S 2 Raltegravir (DB06817) âˆ’7.8 1.916"/>
 <result pre="formula Chemical scheme 1 Dolutegravir (DB08930) âˆ’9.4 128.7â€‰nM C20H19F2N3O5 2" exact="Bictegravir" post="(DB11799) âˆ’8.4 0.696 ÂµM C21H18F3N3O5 EBE: Estimated Binding Free"/>
 <result pre="of 3CLpro (see Table 1), we chose two molecules, namely" exact="Paritaprevir" post="(DB09297) and Raltegravir (DB06817). Similarly, for 2â€²-OMTase (see Table"/>
 <result pre="best two drugs were found to be Dolutegravir (DB08930) and" exact="Bictegravir" post="(DB11799). 3.3. Binding pattern of drug molecules against 3CLpro"/>
 <result pre="Three dimensional representation of 3CLpro active site residues interacting with" exact="Paritaprevir" post="(DB09297) (Green). (b) Two dimensional representation of 3CLpro active"/>
 <result pre="Two dimensional representation of 3CLpro active site residues interacting with" exact="Paritaprevir" post="(Green) via Van der Waals interactions (slightly green colour),"/>
 <result pre="interacting with Raltegravir(Orange). The estimated binding free energy (Î&quot;G) of" exact="Paritaprevir" post="against 3CLpro was observed to be âˆ’9.8â€‰kcal/mol, and the"/>
 <result pre="to be âˆ’7.8â€‰kcal/mol, and the inhibitory constant was 1.916â€‰ÂµM. Both" exact="Paritaprevir" post="and Raltegravir were found to be interacting with the"/>
 <result pre="the bottom of the central groove might bind the first" exact="adenine" post="nucleotide conserved as the acceptor of methyl group during"/>
 <result pre="Three dimensional representation of 2â€²-OMTase active site residues interacting with" exact="Bictegravir" post="(DB11799) (Yellow). (d) Two dimensional representation of 2â€²-OMTase active"/>
 <result pre="(Î&quot;G) of âˆ’9.4â€‰kcal/mol, and the inhibition constant was 128.7â€‰nM. Besides," exact="Bictegravir" post="conferred an estimated binding free energy (Î&quot;G) of âˆ’8.4â€‰kcal/mol"/>
 <result pre="the estimated inhibition constant was 0.696â€‰ÂµM. Moreover, both Dolutegravir and" exact="Bictegravir" post="were found to be actively interacting with the catalytic"/>
 <result pre="Asn43, Lys46, Gly71, Gly73, Ser74, Asp75, Asp99, Asn101, Glu203 2" exact="Bictegravir" post="(DB11799) Asp130 Lys170 Asn198 2.43 2.28 2.15 Met42 Leu100"/>
 <result pre="the proteins. Figure 3. The electrostatic surface potential interaction of" exact="Paritaprevir" post="(DB09297) (Green) and Raltegravir (DB06817) (Orange) bound to 3CLpro."/>
 <result pre="The electrostatic surface potential interaction of Dolutegravir (DB08930) (Sand) and" exact="Bictegravir" post="(DB11799) (Yellow) bound to 2â€²-OMTase. The zoomed view is"/>
 <result pre="RMSF, Rg and SASA additionally supported that Raltegravir and also" exact="Paritaprevir" post="could be the most promising candidates which might be"/>
 <result pre="of the MD simulation analysis, PCA supported that Dolutegravir and" exact="Bictegravir" post="could be the most promising drugs capable of inhibiting"/>
 <result pre="the findings of this study. Raltegravir (Markowitz etÂ al., 2007)," exact="Bictegravir" post="(Sax etÂ al., 2017) and Dolutegravir (Cahn etÂ al.,"/>
 <result pre="in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and" exact="dasabuvir" post="for 12weeks. Journal of Hepatology, 64(2), 301â€&quot;307. doi:10.1016/j.jhep.2015.10.00526476290 GimenoA.,"/>
 <result pre="WhiteK., SenGuptaD., ChengA., &amp;amp; QuirkE. (2017). Coformulated bictegravir, emtricitabine, and" exact="tenofovir alafenamide" post="versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial"/>
 <result pre="(2017). Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with" exact="emtricitabine" post="and tenofovir alafenamide, for initial treatment of HIV-1 infection"/>
 <result pre="bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and" exact="tenofovir alafenamide," post="for initial treatment of HIV-1 infection (GS-US-380â€&quot;1490): A randomised,"/>
 <result pre="â€¦ PodsadeckiT. (2015). Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and" exact="ribavirin" post="for hepatitis C in patients co-infected with HIV-1: A"/>
</results>
